Nicole L. Stone, Ph.D.
Affiliations: | 2000 | University of Pennsylvania, Philadelphia, PA, United States |
Google:
"Nicole Stone"Mean distance: 15.83 (cluster 11) | S | N | B | C | P |
Parents
Sign in to add mentorRandall Pittman | grad student | 2000 | Penn | |
(Mechanisms underlying dynamic morphological changes during the execution phase of apoptosis.) |
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Bussel JB, Saleh MN, Vasey SY, et al. (2013) Repeated short-term use of eltrombopag in patients with chronic immune thrombocytopenia (ITP). British Journal of Haematology. 160: 538-46 |
Platzbecker U, Wong RS, Verma A, et al. (2013) Randomized, Placebo-Controlled, Phase I/II Trial Of The Thrombopoietin Receptor Agonist Eltrombopag In Thrombocytopenic Patients With Advanced Myelodysplastic Syndromes Or Acute Myeloid Leukemia — A Subgroup Analysis Of Patients Receiving Concomitant Anticancer Therapy Blood. 122: 5214-5214 |
Mittelman M, Assouline S, Briasoulis E, et al. (2012) Eltrombopag Treatment of Thrombocytopenia in Advanced Myelodysplastic Syndromes and Acute Myeloid Leukemia: Results of the 8-Week Open-Label Part of an Ongoing Study Blood. 120: 3822-3822 |
Cheng G, Saleh MN, Marcher C, et al. (2011) Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet (London, England). 377: 393-402 |
Cheng G, Tarantino M, Gernsheimer T, et al. (2009) Platelet Counts Following Eltrombopag Discontinuation in Patients with Chronic Immune Thrombocytopenic Purpura. Blood. 114: 3517-3517 |
Saleh MN, Bussel JB, Cheng G, et al. (2008) Eltrombopag Is Efficacious in Patients with Refractory Chronic Idiopathic Thrombocytopenic Purpura (ITP) - Data from the EXTEND Study Blood. 112: 401-401 |
Cheng G, Saleh MN, Bussel JB, et al. (2008) Oral Eltrombopag for the Long-Term Treatment of Patients with Chronic Idiopathic Thrombocytopenic Purpura: Results of a Phase III, Double- Blind, Placebo-Controlled Study (RAISE) Blood. 112: 400-400 |
Bussel JB, Cheng G, Saleh MN, et al. (2008) Safety and Efficacy of Long-Term Treatment with Oral Eltrombopag for Chronic Idiopathic Thrombocytopenic Purpura. Blood. 112: 3432-3432 |
Bussel JB, Psaila B, Saleh MN, et al. (2008) Efficacy and Safety of Repeated Intermittent Treatment with Eltrombopag in Patients with Chronic Idiopathic Thrombocytopenic Purpura. Blood. 112: 3431-3431 |
Cheng G, Bussel JB, Saleh MN, et al. (2008) Eltrombopag Delivers Clinical Benefit in Chronic Idiopathic Thrombocytopenic Purpura (ITP) Patients Not Achieving Platelet Counts ≥50,000/μL - Data from the EXTEND Study. Blood. 112: 3430-3430 |